-
Lilly's Q3 performance exceeded expectations but lowered its annual profit guidance despite a surge in revenue from "weight loss pills"
Eli Lilly's Q3 performance exceeded expectations but lowered its annual profit guidance due to a surge in revenue from "weight loss pills". Prior to Thursday's trading session, American pharmaceutica ... -
Industry shock! Lilly slimming pills have been approved by the US FDA and officially entered the "Two Strong Competition"
Industry shock! Lilly slimming pills have been approved by the US FDA to officially enter the "Two Strong Competition". On Wednesday (November 8th) local time, the US Food and Drug Administration (FD ... -
Novo Nordisk CEO: Negotiating pricing agreement for weight loss drug Wegovy with healthcare system
Lars Fruergaard Jorgensen, CEO of Novo Nordisk, told the Financial Times that Novo Nordisk is in talks with the healthcare system about an innovative pricing agreement for its weight loss drug Wegovy ... -
Is the dual monopoly situation of Novo Nordisk Lilly in danger? By 2029, there may be 16 GLP-1 weight loss drugs on the market
According to analysts from Morningstar and Pitchbook, it is estimated that there will be 16 new GLP-1 drugs launched in the weight loss drug market by 2029, competing for the lucrative market current ... -
Novo Nordisk faces US Senate inquiry over weight loss drug prices
According to the website of the United States Senate, the Senate will hold a hearing on September 24 local time to examine whether Novo Nordisk provides overpriced smeglutide products Ozempic and Weg ...